The classification of acute leukaemia

Area of Science:

• Hematology
• Immunology
• Cytogenetics

Background:

• Standard acute leukaemia classification relies on morphology, cytochemistry, and membrane markers.
• Advances in immunology, particularly lineage-specific monoclonal antibodies (McAb), offer objective diagnostic criteria for acute lymphoblastic leukaemia (ALL).
• Monoclonal antibodies are crucial for classifying certain acute myeloid leukaemias (AML), such as AML-M7 (megakaryoblastic leukaemia) and AML-MO (myeloblastic leukaemia with minimal differentiation).

Purpose of the Study:

• To highlight the role of monoclonal antibodies in refining acute leukaemia classification.
• To address challenges in diagnosing biphenotypic leukaemia and propose evaluation criteria.
• To define the role of karyotyping and cytogenetic abnormalities in diagnosing specific acute leukaemia subtypes.

Main Methods:

• Utilized monoclonal antibodies for lineage-specific antigen detection in leukaemic cells.
• Developed a scoring system for evaluating biphenotypic leukaemia.
• Integrated cytogenetic analysis, including karyotyping and molecular techniques, to identify specific chromosome translocations.

Main Results:

• Monoclonal antibodies provide objective criteria for diagnosing ALL and specific AML subtypes.
• A proposed scoring system aids in recognizing biphenotypic leukaemia as a distinct entity.
• Specific chromosome translocations, such as t(9;22) and t(4;11) in infant ALL, and t(8;16) in AML, are essential for diagnosing certain leukaemia forms.

Conclusions:

• Monoclonal antibodies have significantly advanced acute leukaemia diagnosis and classification.
• Standardized criteria for biphenotypic leukaemia and cytogenetic abnormalities are crucial for accurate diagnosis and disease definition.
• The integration of immunological, cytochemical, morphological, and cytogenetic data provides a comprehensive approach to acute leukaemia classification.